Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antifungal Agents | 5 | 2024 | 296 | 1.350 |
Why?
|
| Hematologic Neoplasms | 2 | 2024 | 294 | 1.240 |
Why?
|
| Bacteremia | 2 | 2019 | 420 | 0.900 |
Why?
|
| Candida tropicalis | 1 | 2024 | 17 | 0.880 |
Why?
|
| Candidiasis, Invasive | 1 | 2024 | 23 | 0.860 |
Why?
|
| Anti-Bacterial Agents | 7 | 2022 | 2519 | 0.820 |
Why?
|
| Candidemia | 3 | 2015 | 44 | 0.820 |
Why?
|
| Vancomycin | 3 | 2022 | 221 | 0.810 |
Why?
|
| Mycoses | 2 | 2021 | 112 | 0.770 |
Why?
|
| Mastoiditis | 1 | 2022 | 33 | 0.730 |
Why?
|
| Rat-Bite Fever | 1 | 2021 | 4 | 0.730 |
Why?
|
| Streptobacillus | 1 | 2021 | 4 | 0.730 |
Why?
|
| Lyme Neuroborreliosis | 1 | 2021 | 3 | 0.730 |
Why?
|
| Autoimmune Hypophysitis | 1 | 2021 | 5 | 0.720 |
Why?
|
| Skin Diseases | 1 | 2022 | 137 | 0.690 |
Why?
|
| Near Drowning | 1 | 2021 | 29 | 0.670 |
Why?
|
| Procyonidae | 1 | 2020 | 1 | 0.670 |
Why?
|
| Bites and Stings | 1 | 2020 | 27 | 0.650 |
Why?
|
| Drowning | 1 | 2021 | 47 | 0.650 |
Why?
|
| Cellulitis | 1 | 2020 | 62 | 0.640 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 231 | 0.630 |
Why?
|
| Salmonella Infections | 1 | 2019 | 31 | 0.620 |
Why?
|
| Hand | 1 | 2020 | 97 | 0.620 |
Why?
|
| Abscess | 1 | 2020 | 138 | 0.600 |
Why?
|
| Photorhabdus | 1 | 2018 | 2 | 0.580 |
Why?
|
| Disease Management | 2 | 2021 | 544 | 0.570 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2018 | 22 | 0.570 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 264 | 0.570 |
Why?
|
| Neonatal Sepsis | 1 | 2018 | 40 | 0.550 |
Why?
|
| Child | 16 | 2024 | 25296 | 0.440 |
Why?
|
| Amphotericin B | 2 | 2022 | 90 | 0.420 |
Why?
|
| Infant | 10 | 2024 | 12806 | 0.410 |
Why?
|
| Child, Preschool | 11 | 2024 | 14462 | 0.410 |
Why?
|
| Retrospective Studies | 10 | 2024 | 17076 | 0.380 |
Why?
|
| Adolescent | 12 | 2025 | 20154 | 0.350 |
Why?
|
| Candida | 1 | 2011 | 79 | 0.340 |
Why?
|
| Bartonella | 1 | 2010 | 10 | 0.330 |
Why?
|
| Bartonella Infections | 1 | 2010 | 7 | 0.330 |
Why?
|
| Retinitis | 1 | 2010 | 12 | 0.330 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2024 | 823 | 0.300 |
Why?
|
| Female | 17 | 2024 | 68733 | 0.280 |
Why?
|
| Humans | 23 | 2025 | 127455 | 0.280 |
Why?
|
| Male | 14 | 2024 | 62861 | 0.240 |
Why?
|
| Orf virus | 1 | 2025 | 5 | 0.230 |
Why?
|
| Ecthyma, Contagious | 1 | 2025 | 6 | 0.230 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8368 | 0.230 |
Why?
|
| Drug Resistance, Fungal | 1 | 2024 | 28 | 0.220 |
Why?
|
| Soft Tissue Infections | 1 | 2025 | 88 | 0.210 |
Why?
|
| Cough | 1 | 2023 | 97 | 0.190 |
Why?
|
| Pleural Effusion | 1 | 2023 | 106 | 0.190 |
Why?
|
| Phaeohyphomycosis | 1 | 2022 | 10 | 0.190 |
Why?
|
| Cerebral Ventriculitis | 1 | 2022 | 16 | 0.190 |
Why?
|
| Central Nervous System Infections | 1 | 2022 | 20 | 0.190 |
Why?
|
| Incidence | 2 | 2024 | 3263 | 0.180 |
Why?
|
| Cephalosporins | 1 | 2022 | 137 | 0.180 |
Why?
|
| Arthritis, Infectious | 1 | 2021 | 65 | 0.170 |
Why?
|
| Aggregatibacter actinomycetemcomitans | 1 | 2020 | 5 | 0.170 |
Why?
|
| Exanthema | 1 | 2021 | 73 | 0.170 |
Why?
|
| Pets | 1 | 2020 | 19 | 0.160 |
Why?
|
| Fusobacterium nucleatum | 1 | 2020 | 19 | 0.160 |
Why?
|
| Risk Factors | 4 | 2024 | 10631 | 0.160 |
Why?
|
| Clinical Clerkship | 1 | 2020 | 67 | 0.160 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 735 | 0.150 |
Why?
|
| Fever | 1 | 2021 | 309 | 0.150 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 165 | 0.150 |
Why?
|
| Acute Disease | 1 | 2022 | 1142 | 0.150 |
Why?
|
| Area Under Curve | 1 | 2019 | 303 | 0.140 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2020 | 156 | 0.140 |
Why?
|
| HIV Infections | 1 | 2010 | 1954 | 0.140 |
Why?
|
| Ceftazidime | 1 | 2018 | 46 | 0.140 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 102 | 0.140 |
Why?
|
| Intensive Care Units | 1 | 2021 | 497 | 0.130 |
Why?
|
| Rhinitis | 1 | 2017 | 41 | 0.130 |
Why?
|
| Sinusitis | 1 | 2017 | 116 | 0.120 |
Why?
|
| Students, Medical | 1 | 2020 | 338 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 535 | 0.120 |
Why?
|
| Rats | 1 | 2021 | 3397 | 0.120 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2018 | 472 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2018 | 398 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2018 | 393 | 0.110 |
Why?
|
| Body Weight | 1 | 2019 | 971 | 0.110 |
Why?
|
| Algorithms | 1 | 2021 | 1638 | 0.110 |
Why?
|
| Hypokalemia | 1 | 2012 | 40 | 0.090 |
Why?
|
| Animals | 3 | 2025 | 33205 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 291 | 0.090 |
Why?
|
| Kidney | 1 | 2018 | 1283 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 664 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2019 | 12580 | 0.080 |
Why?
|
| Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 1 | 2010 | 2 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2012 | 954 | 0.080 |
Why?
|
| Organophosphonates | 1 | 2010 | 21 | 0.080 |
Why?
|
| Oxazines | 1 | 2010 | 28 | 0.080 |
Why?
|
| Age Distribution | 1 | 2011 | 423 | 0.080 |
Why?
|
| Texas | 2 | 2025 | 3565 | 0.080 |
Why?
|
| Deoxycytidine | 1 | 2010 | 82 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3720 | 0.080 |
Why?
|
| Doxycycline | 1 | 2010 | 119 | 0.080 |
Why?
|
| Adenine | 1 | 2010 | 116 | 0.080 |
Why?
|
| Time Factors | 1 | 2019 | 6169 | 0.080 |
Why?
|
| Lung | 2 | 2023 | 1522 | 0.080 |
Why?
|
| Rifampin | 1 | 2010 | 118 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2010 | 271 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2015 | 3331 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2012 | 482 | 0.070 |
Why?
|
| Anti-HIV Agents | 1 | 2010 | 346 | 0.060 |
Why?
|
| Biopsy | 1 | 2010 | 1237 | 0.060 |
Why?
|
| Goats | 1 | 2025 | 60 | 0.060 |
Why?
|
| Sheep | 1 | 2025 | 224 | 0.060 |
Why?
|
| Neoplasms | 1 | 2018 | 2856 | 0.050 |
Why?
|
| Dyspnea | 1 | 2023 | 156 | 0.050 |
Why?
|
| Ascomycota | 1 | 2022 | 27 | 0.050 |
Why?
|
| Skin | 1 | 2025 | 517 | 0.050 |
Why?
|
| Young Adult | 2 | 2017 | 9703 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2022 | 272 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 623 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 972 | 0.040 |
Why?
|
| Nafcillin | 1 | 2018 | 13 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 1310 | 0.040 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 15 | 0.040 |
Why?
|
| Clindamycin | 1 | 2018 | 40 | 0.040 |
Why?
|
| Acetazolamide | 1 | 2018 | 27 | 0.040 |
Why?
|
| Learning | 1 | 2020 | 358 | 0.030 |
Why?
|
| Debridement | 1 | 2017 | 89 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 631 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2023 | 2048 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 489 | 0.030 |
Why?
|
| Endoscopy | 1 | 2017 | 280 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 1791 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2018 | 1047 | 0.030 |
Why?
|
| Health Personnel | 1 | 2018 | 535 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 2111 | 0.020 |
Why?
|
| Parents | 1 | 2018 | 1077 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 3937 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2006 | 33 | 0.020 |
Why?
|
| Camptothecin | 1 | 2006 | 76 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2006 | 236 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 689 | 0.010 |
Why?
|
| Middle Aged | 2 | 2018 | 27867 | 0.010 |
Why?
|
| Adult | 2 | 2018 | 30579 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1601 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2006 | 1501 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 1291 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 5160 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2006 | 3594 | 0.010 |
Why?
|
| Aged | 1 | 2006 | 20494 | 0.000 |
Why?
|